Close Menu

Janssen

Qiagen's test is intended to identify advanced bladder cancer patients with alterations in FGFR3 or FGFR2 genes and who are likely to respond to erdafitinib.

Somalogic will use its SomaScan platform to analyze at least 15,000 clinical samples from Janssen to identify protein biomarkers for various diseases.

Janssen R&D will use BiomX's microbiome-based biomarker discovery platform to identify IBD patients likely to respond to a particular therapy.

The companies will evaluate the performance of Proteomics International's PromarkerD test for predicting decline in kidney function and drug response.

The company is planning to submit the drug and a companion diagnostic that can identify patients with FGFR alterations with the FDA in the second half of 2018.

GenomeDx will test its Decipher GRID database of cancer genomic profiles with samples from Janssen-run prostate cancer clinical trials.

Genomic Health will test samples from Janssen prostate cancer drug studies to examine whether its test can predict patient outcomes.

Adaptive Biotechnologies will measure minimal residual disease in multiple myeloma patients as part of an Amgen-sponsored clinical trial.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

The panel, developed by collaborator Janssen, is expected to improve detection of influenza and respiratory syncytial virus.

Pages

The Oregon state Senate unanimously passed a bill that would make it easier for people convicted of crimes to initiate DNA testing of evidence, according to the Associated Press.

People reports that researchers have uncovered genetic variants that lead people to always feel full.

Florida state senators are to weigh a bill prohibiting life insurance companies from using genetic information in coverage decisions, according to Florida Politics.

In Genome Research this week: metagenomic sequencing assay that detects pathogens in cerebrospinal fluid, single-tube long fragment read approach, and more.